IN10018 is a highly potent and selective inhibitor of the focal adhesion kinase (FAK). Anti-tumor activities of IN10018 have been demonstrated in multiple animal models for human cancers. More than 250 patients have been dosed and IN10018 has showed its safety and promising efficacy signal in platinum ovarian cancer and NRAS melanoma.
IN10018 is now with multiple indications in ongoing clinical trials including NRAS mutant Metastatic Melanoma, Platinum-resistant Ovarian Cancer, TNBC, PDAC etc. IN10018 received fast track designation from the U.S. Food and Drug Administration (FDA) in August 2021, and breakthrough designation from China National Medical Products Administration (NMPA)
Broad Synergies with Multiple Therapeutic Modalities
IN10018 is expected to overcome the tumor-associated fibrosis barrier and improve local immunity through modulating tumor microenvironment (TME) . It therefore has the potential to act as an important anchor molecule in synergy with different therapeutics. The latest research results and preclinical data demonstrated IN10018 great synergy in pre-clinical with multiple therapeutic modalities including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, etc.
FAK is a non-receptor tyrosine kinase and artigma transmitter that plays an important role in cell adhesion, migration, and regulation. It exhibits expression upregulation in multiple tumor types. Researchers have found that inhibiting the FAK signaling pathway can effectively reverse previously failed chemotherapy and targeted therapy caused by drug resistance and enhance the response and efficacy of immunotherapy for solid tumors.
Dawson JC, et al. Nat Rev Cancer. 2021 May;21(5):313-324